Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03673592
Other study ID # IGX14-MOS-AC-18-03
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 3, 2018
Est. completion date May 20, 2020

Study information

Verified date October 2020
Source Igenomix
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Mosaicism within an embryo is defined as the presence of two or more cell populations with different genotypes. Blastocysts classified as mosaic by Preimplamtation Genetic Testing for Aneuploidy (PGT-A) have been reported to implant less and miscarry more frequently than embryos classified as euploid. Because of the unknown impact of mosaicism on embryo development, these embryos are given low priority and are discarded for transfer. However, recent papers on the transfer of human embryos classified by PGT-A as mosaic suggest that embryos with a low fraction of abnormal cells resulting in viable, chromosomally normal ongoing pregnancies, and high-level mosaics resulting in fewer viable pregnancies, but so far none producing mosaic babies. The apparent presence of mosaicism in an embryo is used as a selection criteria for embryo transfer (ET), introducing a strong bias in terms of patient prognosis and embryo quality. Additionally, it is also possible that some embryos are incorrectly classified as "mosaic" due to technical variability derived from the processing of a uniform aneuploid embryo. The aims of this study is to provide evidences about the clinical significance of chromosomal mosaicism in PGT-A cycles by a prospective non-selection based methodology.


Description:

One of the most common reasons why in vitro fertilization (IVF) is unsuccessful, or why miscarriages occur, is because of chromosomal abnormalities in the embryo. Embryos with less than 20% aneuploidy are considered as euploid, while those between 20-80% are reported as mosaic, and those over 80% as aneuploid. Embryos with the correct number of chromosomes (euploid) have a higher chance of leading to a successful pregnancy than those with the incorrect number of chromosomes (aneuploid) or mosaics. Mosaicism within an embryo is defined as the presence of two or more cell populations with different genotypes. Preliminary data suggested that embryos identified as mosaic by Preimplamtation Genetic Testing for Aneuploidy (PGT-A) may have a reduced chance of implantation compared with euploid and may play a significant role in pregnancy loss. Because of the unknown impact of mosaicism on embryo development, these embryos are given low priority and are discarded for transfer. They are transferred mostly in poor prognosis patients, explaining the reported lower clinical performances. However, other recent data regarding the transfer of embryos diagnosed as mosaic has shown that embryos with a low fraction of abnormal cells may result in viable, chromosomally normal ongoing pregnancies. The apparent presence of mosaicism in an embryo is used as a selection criteria for embryo transfer (ET), introducing a strong bias in terms of patient prognosis and embryo quality. Additionally, it is also possible that some embryos are incorrectly classified as mosaic due to technical variability derived from the processing of a uniform aneuploid embryo. Thus, there is an urgent need to understand how to appropriately select and counsel patients regarding such embryos. This study aims to provide evidences about the clinical significance of chromosomal mosaicism in PGT-A cycles by a prospective non-selection based methodology. The objectives are to investigate the clinical predictive value for intermediate copy number results consistent with the presence of low mosaicism in TE biopsies, and to validate the thresholds for the classification of embryos in relation with their reproductive potential, providing comprehensive data for clinicians and patients. To demonstrate these objectives, a total of 878 participants are expected to be recruited in 18 months. As the datapoints required for comparison concern embryo transfers rather than participants, this number could be lower depending on the number of embryo transfers received by each participant.


Recruitment information / eligibility

Status Completed
Enrollment 783
Est. completion date May 20, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 44 Years
Eligibility Inclusion Criteria: - PGT-A cases for any medical indication and sign the written informed consent form approved by the Ethics Committee (EC) after having been duly informed of the nature of the research and voluntarily accepted to participate in the study. - Only PGT-A cycles with own oocytes. - Female age up to 44 years old (also included). - ICSI treatment must be done in all oocytes. - Have at least one euploid blastocyst or one low-grade mosaicism diagnosis for a single chromosome after PGT-A analysis (excluding aneuploidies compatible with life, e.g. chromosomes 13, 18, 21 and X/Y). - Single or Double Embryo Transfer (SET or DET). The patient remains included in the study until the 4th ET (fresh or frozen) from the initial stimulation cycle or until patient's enrolment period ends (whichever comes first). The data collected until one of these points will be included in the study, whilst clinical outcomes from additional ET will be disregarded. Exclusion Criteria: - No embryo reaching blastocyst stage with a proper morphology for trophectoderm biopsy. - Embryo transfer coming from the worst grade blastocyst morphology according to Gardner's criteria (Annex 1) will be excluded. - DET resulting in singletons. (Note: DET resulting in dizygotic twins or implantation failure to the both embryos transferred will be allowed). - Any illness or medical condition that is unstable or can put patient safety at risk and compliance in the study.

Study Design


Intervention

Diagnostic Test:
PGT-A
PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.

Locations

Country Name City State
Italy Demetra Florence
Italy Genera Roma
Italy Humanitas Fertility Center Roma

Sponsors (1)

Lead Sponsor Collaborator
Igenomix

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sustained implantation rate Presence of a viable pregnancy after 20 weeks of gestation measured by ultrasound scan 20 weeks after the embryo transfer
Secondary Miscarriage rate The spontaneous loss of an intra-uterine pregnancy prior to 20 completed weeks of gestational age. 20 weeks after the embryo transfer
See also
  Status Clinical Trial Phase
Completed NCT02268786 - Single Embryo TrAnsfeR of Euploid Embryo N/A
Completed NCT01574404 - Polar Body Biopsy for Preimplantation Genetic Screening N/A
Not yet recruiting NCT03981120 - The Effect of Acupuncture on Pregnancy Rates in Women Undergoing in Vitro Fertilization With Preimplantation Genetic Screening N/A
Recruiting NCT05545995 - Time Lapse Assisted Embryo Selection Versus Non Invasive PGT-A Assisted Embryo Selection
Recruiting NCT05547555 - Invasive PGT-A Embryo Selection Versus Non Invasive PGT-A Assisted Embryo Selection
Completed NCT02787486 - Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Active, not recruiting NCT04865367 - How Secreted-embryo-derived Trypsin Initiates, Maintains and Terminates Ca2+ Signals in Uterine Epithelial Cells
Completed NCT01052688 - Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies
Completed NCT03816423 - Use of Videos to Improve Patient Knowledge on Prenatal Genetics N/A
Recruiting NCT03449225 - Prenatal Computer-Aided Genetics Education Module N/A
Completed NCT03860064 - Aneuploidy Rates of in Vitro Matured Oocytes
Recruiting NCT04000152 - RCT Study to Validate niPGT-A Clinical Benefit. N/A
Recruiting NCT06419127 - Embryo Assessment Utilizing Timelapse Imaging in Conjunction With Preimplantation Genetic Testing for Aneuploidy With Next Generation Sequencing
Active, not recruiting NCT04901247 - A Time-lapse Monitoring Prospective Study
Active, not recruiting NCT05492981 - Does an Educational Video for Aneuploidy Screening Improve Informed Choice Among Pregnant Women? N/A
Completed NCT04420858 - Effect of Video Education on Patients' Knowledge and Attitudes of Privacy in Prenatal Genetics N/A
Completed NCT01597063 - Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies N/A
Completed NCT02284399 - National Prevalence and Impact of Noninvasive Prenatal Testing
Terminated NCT01545674 - Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial
Completed NCT02991729 - Use of a Novel Computerized Decision Aid for Prenatal Aneuploidy Screening N/A